Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243867 · ClinicalTrials.gov registry record · Phase 3
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 518
- Enrollment target
NCT00243867 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 518 participants.
The verdict
NCT00243867, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 518 participants
- Enrollment target
Study Summary
The primary objective of this trial is to compare the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with carboplatin to those treated with paclitaxel plus carboplatin in a prospectively randomized trial. In addition, the response rate to each regimen, response duration, time to progression and time to treatment failure will be measured. Toxicity will be evaluated and compared between the two groups.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Taxoprexin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00243867
The ClinicalTrials.gov registry entry for NCT00243867 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00243867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00243867 about?
NCT00243867 is a clinical study titled "Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer". The primary objective of this trial is to compare the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with carboplatin to those treated with paclitaxel plus carboplatin in a prospectively randomized trial. In addition, the response ...
What is the current status of trial NCT00243867?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 518 participants. The study started on 2005-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00243867?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Taxoprexin (DRUG).
Who is sponsoring clinical trial NCT00243867?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.